



# ARIZONA HOUSE OF REPRESENTATIVES

Fifty-sixth Legislature  
Second Regular Session

## **HB 2105: psilocybin research**

**Sponsor: Representative Payne, LD 27**

**Committee on Military Affairs & Public Safety**

### **Overview**

Modifies regulations relating to the awarding of psilocybin research grants by the Department of Health Services (DHS).

### **History**

[Laws 2023, Chapter 133, Section 44](#), appropriated \$5,000,000 from the state General Fund to DHS for psilocybin research grants in FY 2024. These grants were to be awarded for the purpose of conducting clinical trials to evaluate whole mushroom psilocybin's effectiveness in treating specified mental and physiological disorders. Additionally, a Psilocybin Research Advisory Council (Advisory Council) was established to oversee the grant process ([Laws 2023, Chapter 139, Section 6](#)).

Psilocybin is a hallucinogenic chemical obtained from certain types of fresh or dried mushrooms; it is currently a schedule I controlled substance under federal law ([DEA Fact Sheet, Psilocybin](#)).

### **Provisions**

1. Permits a grant applicant to apply for a grant specific to the current clinical trial phase to be conducted. (Sec. 1)
2. Modifies the membership of the Advisory Council by requiring the physician on the Advisory Council to have experience conducting clinical research with schedule I drugs. (Sec. 1)
3. Prohibits members of the Advisory Council from applying for a grant. (Sec. 1)
4. Exempts the \$5,000,000 appropriated for grants in FY 2024 from lapsing until July 1, 2026. (Sec. 2)
5. Contains an emergency clause. (Sec. 3)

Prop 105 (45 votes)     Prop 108 (40 votes)     Emergency (40 votes)     Fiscal Note